Skip to content

Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension and High Uterosacral Ligament Suspension for Treatment of Middle Compartment Prolapse: A Multicenter Prospective Randomized Controlled Study

Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension and High Uterosacral Ligament Suspension for Treatment of Middle Compartment Prolapse: A Multicenter Prospective Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091145
Enrollment
Unknown
Registered
2024-10-22
Start date
2024-10-23
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic organ prolapse

Interventions

Two:Transvaginal Natural Orifice Endoscopic High Uterosacral Ligament Suspension
One:Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Patients who have completed childbearing and have no desire for fertility; (2) Patients who refuse conservative treatment or have failed conservative treatment; (3) Patients who are willing to undergo surgery and are having their first pelvic organ prolapse surgery; (4) Patients with a POP-Q score indicating uterine prolapse of grade II or higher, combined with other prolapse within the hymenal margin in the mid-pelvic region; (5) Urinary incontinence may be present; (6) Patients who can comply with regular follow-up after surgery.

Exclusion criteria

Exclusion criteria: (1) Patients who subjectively reject this surgical option; (2) Patients with a history of pelvic prolapse surgery; (3) Patients who have previously undergone hysterectomy; (4) Patients with a strong desire to preserve the uterus; (5) Patients with severe internal and external medical conditions, tumors, infections, or bleeding that make them unsuitable for surgery; (6) Patients suspected or diagnosed with pelvic malignancies.

Design outcomes

Primary

MeasureTime frame
Surgical success outcomes;

Secondary

MeasureTime frame
Primary perioperative evaluation indicators;Functional outcomes;postoperative complications;

Countries

China

Contacts

Public ContactYisong Chen

Obstetrics and Gynecology Hospital of Fudan University

cys373900207@163.com+86 136 0191 3713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026